|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course. | Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt | 2014 | World Journal of Gastroenterology2014，20，35： | 2 |
| 2 | Combination chemotherapy with gemcitabine/oxaliplatin in patients (pts) with relapsed or cisplatinrefractory germ-cell cancer (C-CT)显示文摘 | Bokemeyer C Beyer J Metzner B | 2003 | Proc Am Soc Clin Oncol2003，22，： | 1 |
| 3 | A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，： | 1 |
| 4 | Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists显示文摘 | Spath B Hansen A Bokemeyer C | | 0，，1： | 1 |
| 5 | S3-Leitlinie ?Diagnostik und Therapie des Morbus Crohn”显示文摘 | J Hoffmann J Prei? F Autschbach H Buhr W H?user K Herrlinger W H?hne S Koletzko C Krieglstein W Kruis H Matthes G Moser M Reinshagen G Rogler S Schreiber A Schreyer B Sido B Siegmund A Stallmach B Bokemeyer E Stange M Zeitz | 2008 | Z Gastroenterol2008，，09： | 1 |
| 6 | Functional imaging of the brain in patients with liver cirrhosis 显示文摘 | Weissenborn K Bokemeyer M Ahl B | 2004 | Metabolic Brain Disease2004，19，： | 1 |
| 7 | A phase Ⅱ trial of weekly irinotecan in cisplatin-refractory esophageal cancer 显示文摘 | Burkart L Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，4： | 1 |
| 8 | A phase H trial ofweekly irinotecan in cisplatin-refractory esophageal cancer 显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，4： | 1 |
| 9 | Cerebral metabolic altera- tions and cognitive dysfunction in chronic kidney disease显示文摘 | Tryc A B Alwan G Bokemeyer M | 2011 | Neph tol Dial Transplant2011，26，8： | 1 |
| 10 | A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，4： | 1 |
| 11 | Mesalazine in left-sided ulcerative colitis:Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing显示文摘 | Bokemeyer B Hommes D Gill I | 2012 | Journal of Crohn''s and Colitis2012，6，4： | 1 |
| 12 | A phase II trial of weekly irinotecan in cisplatin-refractory esophagealcancer显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，4： | 1 |
| 13 | A phase Ⅱ trial of weekly irinotecan in cispla- tin refractory esophageal cancer 显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anti- cancer Res2007，27，4： | 1 |
| 14 | A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，4： | 1 |
| 15 | Screening colonoscopy for eolorectal cancer prevention: results from a German online regis- try on 269000 cases 显示文摘 | Bokemeyer B Bock H Huppe D | 2009 | Eur J Gastroenterol Hepatol2009，21，6： | 1 |
| 16 | Second European evidence - based consensus on the diagnosis and management of ul- cerative colitis part 3 : special situations 显示文摘 | Van Assche G L Dignass A Bokemeyer B | 2013 | J Crohns Colitis2013，7，1： | 1 |
| 17 | Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis 显示文摘 | Dignass A U Bokemeyer B Adamek H | 2009 | Clin Gastroenterol Hepato12009，7，7： | 1 |
| 18 | A phase II tri- al of weekly irinotecan in cisplatin-refractory esophageal cancer显示文摘 | Burkart C Bokemeyer C Klump B | 2007 | Anticancer Res2007，27，4： | 1 |
| 19 | Asymptomatische Erh?hung von Lipase und Amylasebei Morbus Crohn und Colitis ulcerosa显示文摘 | B Bokemeyer | 2002 | Z Gastroenterol2002，，： | 1 |
| 20 | Mesalazine in left - sided ul- cerative colitis: Efficacy analyses from the PODIUM trim on maintenance of remission and mucosal healing 显示文摘 | Bokemeyer B Hommes D Gill I | 2012 | J Crohns Colitis2012，6，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员